Physician profile
Kenneth Norton
NPI 1972641629
$1,837.84
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $613 · 2021: $222.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $437.63 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $405.38 | 2019 | |
| Daiichi Sankyo INC. | $244.21 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $172.26 | 2019-2020 | |
| Esperion Therapeutics, INC. | $145.84 | 2020 | |
| Abbvie INC. | $137.20 | 2020-2021 | |
| Astellas Pharma US INC | $127.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $91.55 | 2019-2021 | |
| Pfizer INC. | $48.53 | 2019-2021 | |
| Abbott Laboratories | $15.21 | 2021 | |
| Lilly USA, LLC | $12.75 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Norton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.